Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)

NCT05538663 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT05538663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05538663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 7, 2023
Completion date
October 31, 2030
Enrollment
870 (estimated)
Sites
229

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle-invasive bladder cancer